T1	intervention 10 19	tamoxifen
T2	condition 23 51	venous thromboembolic events
T3	total-participants 490 494	5408
T4	eligibility 495 516	hysterectomized women
T5	control 559 566	placebo
T8	cv-bin-abs 591 593	28
T9	outcome 594 598	VTEs
T10	iv-bin-abs 614 616	44
T12	cv-bin-abs 1178 1179	1
T13	iv-bin-abs 1203 1205	13
T14	outcome 1227 1240	developed VTE
T11	outcome 863 874	risk of VTE
